KB-1135

RG6139-PD-hIgG4-S228P

Background

RG-6139 (RO-7247669) is under development for the treatment of metastatic solid tumors including metastatic melanoma, triple-negative breast cancer (TNBC), advanced or metastatic renal cell carcinoma, non-small cell lung cancer, metastatic urothelial cancer, ureter cancer, bladder cancer, urethra cancer and esophageal squamous cell carcinoma. It is administered via intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody which acts by targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3).

Specifications

Catalog Number:
KB-1135
Cell Line Name:
RG6139-PD-hIgG4-S228P
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PD1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. 2.A novel bispecific checkpoint inhibitor antibody to preferentially block PD-1 and LAG-3 on dysfunctional TILs whilst sparing Treg activation.
Please enable JavaScript in your browser to complete this form.